124 related articles for article (PubMed ID: 11837793)
1. Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat.
Iba T; Kidokoro A; Fukunaga M; Fuse S; Suda M; Kunitada S; Hara T
Shock; 2002 Feb; 17(2):159-62. PubMed ID: 11837793
[TBL] [Abstract][Full Text] [Related]
2. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model.
Iba T; Kidokoro A; Fukunaga M; Nagakari K; Shirahama A; Ida Y
Crit Care Med; 2005 Feb; 33(2):368-72. PubMed ID: 15699841
[TBL] [Abstract][Full Text] [Related]
3. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Hara T; Yokoyama A; Morishima Y; Kunitada S
Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
[TBL] [Abstract][Full Text] [Related]
4. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
Yamaguchi Y; Okabe K; Liang J; Matsumura F; Ohshiro H; Ishihara K; Matsuda T; Takeya M; Kuratsu JI; Mori K; Yamada S; Ogawa M
Dig Dis Sci; 1999 Dec; 44(12):2568-76. PubMed ID: 10630515
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
[TBL] [Abstract][Full Text] [Related]
6. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
Rogers KL; Chi L; Rapundalo ST; Kramer JB; Gallagher KP
Basic Res Cardiol; 1999 Feb; 94(1):15-22. PubMed ID: 10097826
[TBL] [Abstract][Full Text] [Related]
7. A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.
Kaiser B; Paintz M; Scholz O; Kunitada S; Fareed J
Thromb Res; 2000 Apr; 98(2):175-85. PubMed ID: 10713319
[TBL] [Abstract][Full Text] [Related]
8. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
[TBL] [Abstract][Full Text] [Related]
9. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
Chino D; Fujita Y; Ishii K; Nakayama K
J Pharmacol Sci; 2003 Apr; 91(4):319-29. PubMed ID: 12719661
[TBL] [Abstract][Full Text] [Related]
10. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
[TBL] [Abstract][Full Text] [Related]
11. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
Hara T; Yokoyama A; Ishihara H; Yokoyama Y; Nagahara T; Iwamoto M
Thromb Haemost; 1994 Mar; 71(3):314-9. PubMed ID: 8029795
[TBL] [Abstract][Full Text] [Related]
12. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Yamashita T; Tsuji T; Matsuoka A; Giddings JC; Yamamoto J
Thromb Res; 1997 Jan; 85(1):45-51. PubMed ID: 8983124
[TBL] [Abstract][Full Text] [Related]
13. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
Tanabe K; Morishima Y; Shibutani T; Terada Y; Hara T; Shinohara Y; Aoyagi K; Kunitada S; Kondo T
Thromb Haemost; 1999 May; 81(5):828-34. PubMed ID: 10365760
[TBL] [Abstract][Full Text] [Related]
14. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
Thromb Haemost; 1994 Sep; 72(3):392-6. PubMed ID: 7855790
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
Kim DI; Kambayashi J; Shibuya T; Sakon M; Kawasaki T
J Atheroscler Thromb; 1996; 2(2):110-6. PubMed ID: 9225218
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.
Kaiser B; Jeske W; Walenga JM; Fareed J
Blood Coagul Fibrinolysis; 1999 Dec; 10(8):495-501. PubMed ID: 10636461
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.
Shimbo D; Osende J; Chen J; Robbins J; Shimoto Y; Kunitada S; Fuster V; Badimon JJ
Thromb Haemost; 2002 Nov; 88(5):733-8. PubMed ID: 12428086
[TBL] [Abstract][Full Text] [Related]
18. Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation.
Tanaka M; Arai H; Liu N; Nogaki F; Nomura K; Kasuno K; Oida E; Kita T; Ono T
Kidney Int; 2005 Jun; 67(6):2123-33. PubMed ID: 15882255
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of Porphyromonas gingivalis growth by a factor Xa inhibitor, DX-9065a.
Matsushita K; Imamura T; Tancharoen S; Tatsuyama S; Tomikawa M; Travis J; Potempa J; Torii M; Maruyama I
J Periodontal Res; 2006 Jun; 41(3):171-6. PubMed ID: 16677284
[TBL] [Abstract][Full Text] [Related]
20. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
Rezaie AR
Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
